Ignite Creation Date:
2024-05-05 @ 9:08 PM
Last Modification Date:
2024-10-26 @ 9:59 AM
Study NCT ID:
NCT00819104
Status:
COMPLETED
Last Update Posted:
2009-09-09
First Post:
2009-01-07
Brief Title:
A Study to Compare the Efficacy Safety and Tolerability of Selomax With Its Individual Components
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Five-arm Randomised Open Label Multi-centre Prospective Study to Compare the Efficacy Safety and Tolerability of Metoprolol XL Plus Amlodipine Combination Selomax TM With Metoprolol XL and Amlodipine as Individual Components in Management of Hypertension in Indian Patients
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MARS
Brief Summary:
This is a randomised open-label parallel group multicentric study comparing the efficacy and safety of fixed-dose-combinations of Metoprolol XL plus Amlodipine with individual components of the combination SelomaxTM505 will also be compared with SelomaxTM 2525 in lowering of BP SBP and DBP in Indian patients with essential hypertensionMale and female patients of essential hypertension aged between 18-80 years will be studied The patients should not have a history of prior cardiovascular disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None